Expression of Stress Markers During Meth Treatment (EXPRESS+) — EXPRESS+  

HIV Clinical Trial

Official title: Expression of Stress Markers in MSM Living With HIV Receiving Contingency Management for Methamphetamine Use Disorder

Status Recruiting

Clinical Trial Summary

This is a non-randomized behavioral trial that aims to investigate whether changes in inflammatory and type I IFN expression coincide with changes in methamphetamine use and viral load over the course of 12 weeks in HIV-positive people assigned male at birth with and without methamphetamine use disorder.

Clinical Trial Description

This is a within-subjects, two-arm study with 35 HIV-positive people assigned male at birth receiving contingency management for treatment of methamphetamine use disorder and 20 HIV-positive people assigned male at birth serving as a non-substance-using healthy control (N=55 total). HIV-positive participants with methamphetamine use disorder who meet the eligibility criteria will be assigned to the contingency management treatment group. HIV-positive participants who do not use substances and meet the specific criteria will be assigned to the non-substance-using control group. Participants will be observed over 8 weeks, with another follow-up 4 weeks thereafter. ;

Related Conditions & MeSH terms

• HIV
• Substance-Related Disorders

• NCT number: NCT05558345
• Study type: Interventional
• Source: University of California, Los Angeles
• Contact: Michael J Li, PhD
• Phone: 3107948530
• Email: mjli@mednet.ucla.edu
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2022
• Completion date: March 31, 2026